JMP Securities Maintains Market Outperform on Kura Oncology, Raises Price Target to $32
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Reni Benjamin has reaffirmed a Market Outperform rating on Kura Oncology (NASDAQ:KURA) and increased the price target from $22 to $32, indicating a positive outlook on the company's stock.
January 31, 2024 | 6:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Kura Oncology's stock rating has been maintained at Market Outperform by JMP Securities, with a significant increase in the price target from $22 to $32, suggesting strong confidence in the company's future performance.
The increase in price target by JMP Securities is a strong positive signal to investors, often leading to increased investor confidence and potential short-term price appreciation. The substantial raise from $22 to $32 reflects a significant change in valuation, which could attract more attention to the stock and possibly drive up its price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100